Waldencast PLC WALD

Waldencast plc filed a Form 25 with the SEC to remove its Class A ordinary shares and redeemable warrants from listing on Nasdaq and to deregister these securities under the Exchange Act. Delisting is expected to be effective around October 4, 2026, with the last trading day on Nasdaq around October 2, 2026. The company also plans to file a Form 15 around October 5, 2026 to suspend its reporting obligations under Sections 12(g) and 15(d), with deregistration of 12(b) effectiveness 90 days after Form 25. Waldencast reserves the right to withdraw or postpone filings. The move ends Nasdaq trading and SEC reporting for these securities, according to the company. Removal from Nasdaq and deregistration will reduce liquidity and investor transparency, potentially impacting WALD's access to capital and market sentiment.

Waldencast plc plans to voluntarily delist from Nasdaq and deregister its securities under the Exchange Act. Voluntary Nasdaq delisting and deregistration sharply reduces share liquidity and investor visibility for Waldencast.

Waldencast PLC completed the sale of Obagi Medical to Bridgepoint. Completion of Obagi Medical sale to Bridgepoint constitutes major strategic divestiture for Waldencast.

Obagi Medical gains FDA approval for Obagi saypha ChIQ injectable hyaluronic acid gel. FDA clearance for new injectable product directly expands Obagi's commercial offerings and revenue potential.

Waldencast PLC sells Obagi Medical to Bridgepoint. Sale of Obagi Medical is a major divestiture that alters Waldencast's business portfolio and financial trajectory.

Waldencast (WALD) investment story shifts as financial targets fall short, yet hopes persist for brands like Obagi and Milk + Honee amid ongoing challenges. Falling targets indicate operational shortfalls with moderate effects on financials, balanced by enduring brand optimism.

Obagi Medical, a Waldencast PLC brand, unveiled a new mineral sunscreen formulated to protect sensitive and post-procedure skin. New specialized sunscreen launch by flagship brand Obagi bolsters Waldencast's innovation pipeline and targets high-demand skincare segments.

Waldencast PLC announces the conclusion of an SEC investigation with no enforcement action recommended. Resolution of SEC investigation clears regulatory overhang, significantly improving investor sentiment and market performance.

Obagi Medical introduces NU-GEN™ Cellular Renewal Serum, designed to visibly rewind skin’s age and restore visible youthfulness. Significant product launch by Obagi Medical enhances Waldencast's skincare innovation and potential revenue growth.

Obagi Medical and ProMD announced a collaboration in the ALOHA Program to advance clinical evidence for Obagi saypha MagIQ. Collaboration strengthens clinical validation of a key skincare product, moderately boosting innovation and market positioning.

Waldencast PLC reported Q4 2025 and full-year 2025 financial results. Q4 and FY financial results directly affect stock price, investor confidence, and future performance expectations.

Obagi Medical and Schweiger Dermatology announced a collaboration in the ALOHA Program to generate real-world evidence for Obagi saypha MagIQ, a hyaluronic acid filler, involving data collection from dermatology practices to support clinical validation and market adoption. Partnership with a major dermatology group for real-world evidence on saypha MagIQ strengthens product validation and competitive positioning without fundamentally altering Waldencast's trajectory.

Obagi Medical and It’s a Secret Med Spa announced a collaboration in the ALOHA Program to generate real-world evidence for Obagi saypha MagIQ. Collaboration generates real-world evidence for a key skincare product, moderately boosting validation and competitive positioning.

Waldencast PLC's narrative shifts as outlook resets balance rising brand optimism. Outlook resets tempered by brand optimism moderately influence market sentiment and trajectory.

Obagi Medical and Aesthetic Record announced a collaboration in the ALOHA Program to generate real-world evidence for Obagi saypha MagIQ, enhancing data-driven insights for the aesthetic filler product. Partnership generates real-world evidence for a key Obagi product, moderately boosting validation and competitive edge in aesthetics.

Waldencast PLC (WALD) is experiencing a shift in analysts' perspectives, with increasing scrutiny on its business model and growth potential. Recent evaluations highlight concerns regarding its market positioning and competitive landscape, prompting analysts to reassess their forecasts and recommendations. The company's strategic initiatives and product offerings are under review as stakeholders seek clarity on its long-term viability in a rapidly evolving market. Analysts are reassessing their forecasts, indicating a moderately noticeable influence on Waldencast's financial performance and market positioning.

Obagi Medical and DermFx have announced a collaboration in the ALOHA Program aimed at generating real-world evidence for the Obagi® saypha® MagIQ™ product. This partnership is expected to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies in their market positioning and product development efforts. The collaboration may moderately influence product innovation and market sentiment but is not expected to drastically alter the company's overall trajectory.

Obagi Medical and Moxie have partnered in the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™. This collaboration aims to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies in their market positioning and product development efforts. The collaboration may moderately influence Obagi's product innovation and market presence, but its overall impact on Waldencast's trajectory is expected to be limited.

Obagi Medical has launched a new Lip Therapy Protocol aimed at resurfacing, replenishing, and protecting lips. This innovative protocol is designed to enhance lip health and appearance, addressing common concerns such as dryness and damage. The introduction of this product aligns with Obagi's commitment to providing effective skincare solutions. The launch of a new product may moderately influence Obagi's financial performance and competitive positioning in the skincare market.

Obagi Medical and VIO Med Spa have launched a collaboration under the ALOHA Program aimed at generating real-world evidence for the Obagi® saypha® MagIQ™ product. This partnership seeks to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies and their market positions. The collaboration may enhance product validation and market positioning but is not expected to drastically alter the company's overall trajectory.

Obagi Medical and Next Health have partnered in the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™. This collaboration aims to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies and their market positions. The collaboration may enhance product credibility and market presence, but its overall impact on Waldencast's trajectory is expected to be limited.

Obagi Medical and Alpha Aesthetic Partners have announced a collaboration in the ALOHA Program aimed at generating real-world evidence for Obagi® saypha® MagIQ™. This partnership is expected to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies and their market positioning. The collaboration may moderately influence product innovation and market sentiment but is not expected to drastically alter the company's overall trajectory.

Obagi Medical and Alpha Aesthetic Partners have launched the ALOHA Program, aimed at generating real-world evidence for the Obagi® saypha® MagIQ™ product. This collaboration focuses on enhancing the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies and their market positioning. The collaboration may moderately influence Obagi's product innovation and market presence, but its overall impact on Waldencast's trajectory is expected to be limited.

Obagi Medical and Platinum Dermatology Partners have announced a collaboration in the ALOHA Program aimed at generating real-world evidence for the Obagi® saypha® MagIQ™ product. This partnership is expected to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies in their market positioning. The collaboration may moderately influence product innovation and market sentiment but is not expected to drastically alter Waldencast PLC's overall trajectory.

Obagi Medical and Platinum Dermatology Partners have announced a collaboration in the ALOHA Program aimed at generating real-world evidence for the Obagi® saypha® MagIQ™ product. This partnership is expected to enhance the understanding of the product's effectiveness and safety in practical settings, potentially benefiting both companies and their market positions. The collaboration may moderately influence Obagi's product innovation and market positioning, but its overall effect on Waldencast PLC's trajectory is expected to be limited.

Obagi Medical has launched the ALOHA Program to introduce its new hyaluronic acid filler, Obagi® saypha® MagIQ™. This initiative aims to conduct the largest real-world evaluation of the product, focusing on its effectiveness and safety in aesthetic treatments. The program is expected to enhance the understanding of the filler’s performance in diverse patient populations and contribute to the advancement of aesthetic medicine. The introduction of a new product and its evaluation could moderately influence market positioning and financial performance.

Waldencast PLC is experiencing significant developments that are shaping its investment narrative. Recent strategic initiatives and market dynamics are expected to influence the company's future performance and investor sentiment. The focus on sustainability and innovation in product offerings is positioning Waldencast favorably within its competitive landscape, potentially enhancing its market presence and financial outlook. Strategic initiatives and market dynamics are likely to significantly influence Waldencast's future performance and investor sentiment.

Waldencast PLC reported its Q2 2025 financial results, highlighting key metrics and performance indicators. The company provided a trading update for Q3 2025, outlining expectations and strategic initiatives aimed at enhancing growth. Management emphasized ongoing efforts to innovate and expand market presence, while addressing challenges faced in the current economic environment. The financial results and trading update indicate moderate influences on Waldencast's performance and market positioning.

Obagi Medical presented new clinical data on its Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting, highlighting advancements in their product offerings and potential benefits for patients seeking aesthetic treatments. The presentation of new clinical data may enhance product innovation and competitive positioning but is not expected to drastically alter the company's trajectory.

Waldencast PLC announced a trademark sale for Japan, which is expected to strengthen its balance sheet. Additionally, the company is refinancing its credit facilities, aiming to improve its financial position and operational flexibility. The trademark sale and refinancing are significant strategic moves that could enhance Waldencast's financial stability and market positioning.